DE

The Future Map · technological enabler · active

Longevity & Healthspan Interventions

Maturity

1 / 5

Basis, source, vintage

All human data are early-phase and no biomarker of ageing is accepted by the FDA or EMA as a trial endpoint.

Source: Hickson et al., EBioMedicine 47:446–456 (2019), first-in-human senolytic pilot N=9; UNITY UBX0101 Phase 2 (N=183) missed its primary endpoint, 17 Aug 2020; Ying et al., Nature Aging 4:231–246 (2024) on epigenetic clocks as surrogate endpoints (2019–2024)

What it is

Interventions aimed at the biology of ageing itself — senolytics, metabolic and cellular reprogramming approaches.

What it does

It targets the upstream driver of most age-related disease at once, rather than treating each disease separately. If it works even partially, the demographic and fiscal consequences are large.

Common misconception

That the field has demonstrated human results. Animal data is genuinely striking, human trials are early, and this is among the most overclaimed areas in this Compendium.

Steepens

A megatrend runs at the pace of its shallowest enabler. Marginal links are shown but never set the pace.

What would change its gradient

Shares megatrends with

In the book

Why the Future Arrives Unevenly — Ch. 7 — The Inversion of the Population Pyramid · Ch. 14 — How Hype Is Manufactured

Sources


See it in the map →

Cite this entry

Talin, B. (2026). Longevity & Healthspan Interventions. The Future Map, dataset v0.4.0 (2026-09-07). https://futuremap.talin.digital/e/longevity-and-healthspan-interventions/

Machine view: This entry as Markdown · The whole map as JSON

Updated 2026-09-02.